Hikma Pharmaceuticals Plc Directorate Change (1135R)
25 Giugno 2020 - 2:00PM
UK Regulatory
TIDMHIK
RNS Number : 1135R
Hikma Pharmaceuticals Plc
25 June 2020
Jochen Gann Resigns from the Board of Hikma
London, 25 June 2020 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) ( Hikma ) announces that, following the disposal of
shares by Boehringer Ingelheim Invest GmbH (part of the Boehringer
Ingelheim group of companies which includes Boehringer Ingelheim
International GmbH and Boehringer Ingelheim Corp. ('BI')) and in
accordance with the shareholder agreement between Hikma and BI,
that Dr. Jochen Gann has resigned his directorship of Hikma with
immediate effect.
Said Darwazah, Executive Chairman , said: 'Jochen Gann has
brought a wealth of experience to the Hikma Board. It has been a
pleasure working with Jochen over the last five years and we wish
him well for the future.'
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, EVP Strategy and Global Affairs +44 (0)20 7399
2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,600 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information,
please visit: www.hikma.com
LEI: 549300BNS685UXH4JI75
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPPURAQUPUGGA
(END) Dow Jones Newswires
June 25, 2020 08:00 ET (12:00 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Apr 2023 a Apr 2024